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ABSTRACT
Prostate cancer can transform from androgen-responsive to an androgenindependent phenotype. The mechanism responsible for the transformation remains
unclear. We studied the effects of an epigenetic modulator, phenethyl isothiocyanate
(PEITC), on the androgen-responsive LNCaP cells. After treatment with PEITC, floating
spheres were formed with characteristics of prostate cancer stem cells (PCSC). These
spheres were capable of self-renewal in media with and without androgen. They
have been maintained in both types of media as long term cultures. Upon androgen
deprivation, the adherent spheres differentiated to neuroendocrine cells (NEC) with
decreased proliferation, expression of androgen receptor, and PSA. NEC reverse
differentiated to spheres when androgen was replenished. The sphere cells expressed
surface marker CD44 and had enhanced histone H3K4 acetylation, DNMT1 downregulation and GSTP1 activation. We hypothesize that PEITC-mediated alteration
in epigenomics of LNCaP cells may give rise to sphere cells, whereas reversible
androgenomic alterations govern the shuttling between sphere PCSC and progeny
NEC. Our findings identify unrecognized properties of prostate cancer sphere cells with
multi-potential plasticity. This system will facilitate development of novel therapeutic
agents and allow further exploration into epigenomics and androgenomics governing
the transformation to hormone refractory prostate cancer.

mechanisms responsible for the cancer progression remain
unclear. The most prominent mechanisms postulated to
date involve the androgen receptor (AR). They include AR
gene mutation, excessive recruitment of AR transcription
co-regulators [1, 2], non-AR-related bypass pathways [3],
and epigenetic alterations including hypermethylation of
AR promoter [4]. Other mechanisms postulated include
the involvement of prostate cancer stem cells (PCSC).
Epithelial androgen-independent prostate cancer stem cells

INTRODUCTION
Prostate cancer initially responds to androgen
deprivation therapy but eventually becomes refractory to
hormone therapy. These hormone refractory cancer cells
grow independently of androgen, become highly aggressive,
and metastasize quickly. Hormone refractory prostate
cancer leads to high mortality since there lacks effective
therapy. One major reason is that the precise molecular
www.impactjournals.com/oncotarget
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or AR negative stem cells have been hypothesized to be
present in the prostate cancers which become enriched by
androgen deprivation therapy [5, 6].
Prostate cancer stem cells have been a subject of
our research. We reported in 1999 that the androgendependent human prostate cancer cells LNCaP could be
induced to form neuroendocrine cells by interleukin 1.
These neuroendocrine cells were significantly attenuated
in proliferation and in PSA production [7]. Similarly, Bang
et al reported that LNCaP cells underwent neuroendocrine
cell differentiation mediated by cyclic AMP analogues [8].
Clinical cases of transformation of prostate adenocarcinoma
to neuroendocrine cancer type have been reported [9].
Prostate cancer stem cells (PCSC) have been shown in
spheres from prostate cancer cell line DU-145 [10], from
castration-resistant LNCaP cell line [11], and also from
xenografts of prostate cancer specimen [12]. Spheres
were obtained in cell cultures primarily with the aid of
special culture media or Matrigel which are rich in growth
factors. The characteristics of PCSC within the spheres, the
mechanisms by which they renew and differentiate, as well
as their androgen dependency have yet to be defined.
Epigenetic agents have been shown to be potentially
effective treatments for prostate cancer [13, 14]. We have
demonstrated that phenethyl isothiocyanate (PEITC)
is an epigenetic agent with dual activity to inhibit DNA
hypermethylation and histone deacetylation [15, 16]. In
this study, LNCaP cell spheres were established after
PEITC treatment. The sphere cells expressed cancer
stem cell marker CD44 and had epigenomic alterations
distinct from the parental LNCaP cells. The sphere cells
can self-renew with androgen and also in androgendeprived condition. Furthermore, the sphere cells were
capable of differentiating to neuroendocrine cells (NEC)
when androgen was deprived. The NEC could reversedifferentiate to spheres when androgen was replenished.

derived from the LNCaP cells, a separate LNCaP cell line
expressing green fluorescent protein (GFP-LNCaP) was
examined for sphere development. As shown in Figure 1A
(center, GFP-sphere), the floating spheres with GFP
fluorescence were reproducibly developed from the GFPLNCaP cell line following the same PEITC treatment
protocol. This indicated that the spheres were formed
de novo from the LNCaP cells, not due to contamination
by other cells. Floating spheres could be maintained as
long term culture in flasks with ultralow attachment,
in RPMI-1640 medium and 10% regular FBS without
PEITC, and they do not revert back to parental LNCaP
cells. The spheres could form adherent culture in regular
culture flasks, and had cells migrated outward from the
spheres (Figure 1A right). The spheres were maintained
in the long-term culture with morphology distinct from
the LNCaP cell monolayer culture.
Furthermore, we have also examined the sphere
formation properties of two other prostate cancer cell
lines, PC-3 and DU-145. The sphere formation efficiencies
and sizes of spheres were recorded (Supplementary
Table S1). The quantity of spheres was approximately
less than 0.05% of the starting PC-3 cells, approximately
1/10th of the sphere formation efficiencies from LNCaP
and GFP-LNCaP cell lines. Under similar conditions, no
sphere formation was observed from DU-145. Thus, the
sphere formation property appears to be intrinsic to the
individual cell lines.
To examine the 3D-structure of the spheres, the
spheres were prepared in paraffin blocks for H & E
staining. Figure 1B shows a typical cross section of the
LNCaP spheres (Figure 1B, sphere cross-section). Cells
were shown to line up concentrically, with cell layers
expanding circularly outward from the center. The outer
cell layers were more tightly compacted than those in
the interior. The sphere cells were relatively smaller
than the parental LNCaP cells (Figure 1B, LNCaP),
and displayed different morphology with oval shaped
nuclei, high nuclear-cytoplasmic ratio, irregular nuclear
contour and prominent nucleoli (Figure 1B). The LNCaP
cells prepared identically had eccentric nuclei, irregular
nuclear outlines and intermediate cytoplasm (Figure 1B
left, LNCaP). The proliferation of the sphere cells was
evaluated by immunostaining of Ki67, a marker of cell
proliferation. Ki67 expression was found mainly in the
periphery of the spheres, as shown in a typical staining
(Figure 1B, Ki67 staining). The peripheral location of
Ki67 expression and the concentric cell layers suggested
a spherical growth pattern. To assess the self—renewal
potential of the spheres, single cells from spheres were
seeded with limiting dilution in medium with regular
FBS. New spheres were regularly formed, which could be
maintained for multiple generations and have been kept
as long term cultures for more than two years. In these
cultures the adherent spheres may detach and re-attach to
the culture vessels during culture passage.

RESULTS
Establishment and structure of the prostate
cancer spheres
LNCaP cells were exposed to PEITC at various
concentrations and the development of spheres was
investigated. PEITC at 4 μM was found to be optimal for
mediating the formation of floating spheres after 4-7 days.
There were no floating spheres in the control cultures of
LNCaP cells without PEITC. The spheres were enriched
with continued exposure to 3 μM PEITC for 8-12 days.
With three different lots of LNCaP cell cultures examined,
the number of spheres obtained were approximately
0.46% (ranged from 0.18%-0.62%) of the starting LNCaP
cells. Each floating sphere was initially composed of
several cells, which grew larger in size to form the
characteristic 3D-clusters (Figure 1A left, sphere). To
demonstrate that the PEITC-induced spheres were indeed
www.impactjournals.com/oncotarget
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Spheres grew slower in androgen-deficient
medium

Differentiation of sphere cells to
neuroendocrine cells

To determine the effect of androgen on the sphere
cell growth, the spheres were cultured in medium with
10% steroid hormone-depleted charcoal dextran-stripped
FBS (CSF) which contains lower than castrate level
of testosterone [17]. The sphere cultures in the CSF
medium maintained good viability but grew slower than
the spheres kept in the regular FBS medium. The spheres
have been maintained in both types of media as long term
cultures, and their proliferation was evaluated with cell
cycle phase progression using flow cytometry. Figure 2A
shows that the sphere culture in CSF medium (open bar)
had significantly fewer replicating cells in S and G2M
phases (19.2 ± 2.3%) than those spheres grown in the
regular FBS medium (solid bar) (26.1± 1%)(P=0.022).The
results indicated that the spheres could self-renew in the
presence of androgen, but at a significantly slower rate in
the absence of androgen.

We next examined the differentiation of sphere cells
in the presence and absence of androgen. The monolayer
cells spreading from adherent spheres underwent gradual
morphological changes in the CSF medium, as compared
to sphere cells cultured with regular FBS medium.
The cells became elongated and displayed dendritic
projections which were seen to bridge with other cells
(Figure 2B). The cells had round nuclei, a high nuclearcytoplasmic ratio, and prominent nucleoli (Figure 2B).
This morphology resembles the characteristics of neuroen
docrine cells (NEC) [7, 8]. They were further examined
for the presence of neuroendocrine cell markers by
immunohistochemical staining. As summarized in Table 1,
these cells were positive for serotonin, neuro-specific
enolase, and pan-cytokeratin, the biochemical hallmarks
of NECs. These markers were at background levels in the
LNCaP cells and the spheres (Table 1).

Figure 1: Structure of LNCaP prostate cancer spheres. A. Representative bright-field images of LNCaP cell spheres cultured in

RPMI-1640 medium with 10% FBS. From left to right are floating 3D-sphere, 400x magnifications; fluorescent image of a GFP-labeled
LNCaP cell sphere, 400x magnifications; and an adherent sphere, 200x magnifications. B. The left is an image of H & E stained paraffin
embedded LNCaP cells; the center is a cross section of a sphere, paraffin embedded and H& E stained; and the right is cross section of a sphere,
paraffin embedded and immuno-stained for Ki67 expression. The dark spots are the Ki67 positive cells. Images are 400x magnifications.
www.impactjournals.com/oncotarget
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Figure 2: Growth and differentiation of LNCaP-derived sphere cells. A. Cell cycle analysis of sphere cells. LNCaP sphere

cultures maintained in RPMI-1640 medium with 10% regular FBS (solid column) or with10% charcoal-stripped FBS (CSF) (open column)
were analyzed for cell cycle phase distribution by flow cytometry. Vertical bars are mean ± SD of 3 separate experiments. B. Neuroendocrine
cells developed from adherent sphere cells in medium with 10% CSF on chamber slides, Pap stained, 400 x magnifications. C. Western
blots showing the expression of androgen receptor (AR), Sp1, and PSA in LNCaP cells (maintained in regular FBS medium), spheres
(maintained in regular FBS medium), and neuroendocrine cells (maintained in CSF medium). β-actin was used as a loading control.
D. Immunohistochemical staining of AR in paraffin embedded preparations. From left to right are LNCaP cells, spheres (regular FBS
medium), and neuroendocrine cells (CSF medium), 400x magnifications.

Table 1: Expression of neuroendocrine cell markers
Markers

Staining intensity
LNCaP

Spheres

Neuroendocrine cells

Pancytokeratin

+/−

−

+++

Neuro-specific enolase

+/−

−

+++

−

−

+

Serotonin

Definition of staining intensity: +/− : focally and weakly positive; − : negative; + : weakly positive; +++: strongly positive.
Since NEC differentiation was induced in medium
with charcoal-stripped FBS (androgen-depleted), the
involvement of androgen receptor (AR) in the differen
tiation was investigated. AR expression in the NEC
was at the background level, approximately 2.8 folds
lower than that of the LNCaP cells, and approximately
6.1 folds lower than that of sphere cells (Figure 2C).
www.impactjournals.com/oncotarget

We also examined the expression of the transcription
factor Sp1, which is known to mediate AR transcription
[18, 19]. Sp1 mirrored the expression pattern of AR,
with the LNCaP reduced approximately 5.7 folds than
the spheres while the NEC expressed it only at the
background level (Figure 2C). The level of PSA, which
is a down-stream target gene of AR, also followed the
26570
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expression pattern of AR, in that PSA in the LNCaP was
approximately 7.5 folds lower than that of the sphere
cells, and PSA in NEC was not detectable (Figure 2C).
The reduced AR expression in the NEC was further
verified by immunohistochemical staining of the cells
prepared in paraffin block. Figure 2D shows that the
NEC had a much reduced staining intensity of AR as
compared to the LNCaP cells and the sphere cells.
These results suggest that reduction of AR expression
may be an important mechanism for the differentiation
of spheres to NEC.

than those in the parental LNCaP cells (16.2 ±3.1%).
AR expression in the reverted spheres was significantly
increased, to approximately 5.5 folds more than that in
the NEC (Figure 3B). The morphological and biochemical
changes corroborated the androgen-dependent reversibility
between the spheres and NEC. The plasticity of the sphere
cells supports the notion that these spheres contain prostate
cancer stem cells.

Reversible differentiation between spheres
and neuroendocrine cells

Prostate cancer stem cells have been described to
express surface marker CD44 [20, 21]. Flow cytometric
analyses demonstrated that LNCaP cells had background
level of CD44 staining, whereas approximately 28.1 ±
16 % of the sphere cells grown in regular FBS medium
were positive for CD44 (Figure 4A). The sphere cells
maintained in CSF medium were approximately 35.2 ±
12% positive for CD44, and the NEC approximately 42.2
± 12% CD44–positive (Figure 4A). CD44 may thus be a
sphere marker distinct from the parental LNCaP cells.
Anchorage-independent growth is one of the hallmarks
of cell transformation and tumorigenic potential. To
characterize whether the spheres and NEC have the capability
of anchorage-independent growth, the cells were evaluated
in soft-gel culture. The NEC and the sphere cells all formed
significant number of colonies in soft agar gel, indicating that
both cell types still retained tumorigenic potential. However,
the number of colonies from the NEC (19.5 ± 5.9) was
significantly lower than those from the spheres (46.5 ± 6.4)
and the LNCaP cells (64.8 ± 7.7) (Figure 4B).

Distinct phenotype and invasive activity of
spheres and neuroendocrine cells

When CSF culture medium was replaced with
regular FBS medium for 7-14 days, the neuroendocrine
cells gradually lost the dendritic morphology, and spheres
reappeared on the monolayer, implying that androgen
may propel neuroendocrine cells back to spheres.
To further characterize the effect of androgen on the
reformation of spheres from NEC, dihydrotestosterone
(DHT) was added to the CSF culture medium. Addition
of DHT from 1-80 nM induced sphere formation in a
concentration-dependent manner. DHT at 10 nM was
optimal, with spheres forming in 3-5 days. These spheres
had significantly more replicating cells than the NEC, as
indicated by Ki67 staining (Figure 3A). The spheres had
approximately 28.3 ± 4.2% Ki67 positive cells, a major
increase from 8.4 ± 2.1% of the NEC. The Ki67 level in
the DHT-driven spheres was similar to that of the spheres
grown in regular FBS medium (25.8 ± 3.6%), but more

Figure 3: Reversible differentiation between LNCaP spheres and neuroendocrine cells. A. Immunohistochemical staining of

Ki67 expression in LNCaP cells (maintained in regular FBS medium), spheres (regular FBS medium), neuroendocrine cells (CSF medium),
and spheres reverse differentiated from the neuroendocrine cells (maintained in regular FBS medium). Columns and vertical bars represent
means ± SD of 4 independent experiments. B. Western blots for androgen receptor (AR) expression in the neuroendocrine cells (CSF
medium), spheres reverse differentiated from the neuroendocrine cells (maintained in regular FBS medium), and spheres (maintained in
regular FBS medium). β-actin was used as a loading control.
www.impactjournals.com/oncotarget
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It is well known that carcinomas such as small
cell lung cancer and small cell prostate cancer with
neuroendocrine cell features metastasize early in the
disease course. A Matrigel invasion chamber assay was
used to examine the invasion capacity of the cells. In the
presence of 10% regular FBS, the spheres had the lowest
invasive activity with approximately 8.3 ± 1 invasive cells
per membrane, as compared to the LNCaP cells, with 27.3
±10.2 cells per membrane, and the NEC, with the highest
activity at 37.6 ±12.3 cells per membrane (Figure 4C).
The invasive activity of the NEC in the presence of
charcoal-stripped FBS was approximately 32.6 ±1.2
cells per membrane, similar to that when regular FBS
was used as chemoattractant. This indicates that the
invasive activity of the NEC is independent of androgen.
This property is consistent with the cell nature of these
neuroendocrine cells which developed in the absence of

androgen. The tumor cell type rather than the androgen
level may be the determining factor for chemotaxic
migration and invasion.

Distinct epigenetic signatures of spheres
Epigenetic marks in the spheres were compared
with those in the LNCaP cells. LNCaP cells and the
great majority of clinical prostate tumors are known to
have the π-class glutathione S-transferase gene (GSTP1)
silenced due to promoter hypermethylation [22, 23]. The
expression levels of GSTP1 in the spheres after PEITC
exposure were clearly increased (approximately 6.7
folds) in comparison to that of the untreated LNCaP cells
(Figure 5A). Meanwhile, the expression level of DNA
methyltransferase 1 (DNMT1), an enzyme responsible
for DNA methylation, was significantly reduced in the

Figure 4: Phenotype and invasive activity of sphere and neuroendocrine cells. A. CD44 expression. This figure shows the

proportion of CD44 positive cells among LNCaP cells maintained in regular FBS medium, sphere cells maintained in regular FBS medium,
sphere cells maintained in CSF medium, and neuroendocrine cells maintained in CSF medium, as determined by a flow cytometric method.
Columns and vertical bars represent the means ± SD of four independent experiments. B. Soft-agar gel colony formation assay showing number
of colonies per plate of LNCaP cells (prepared in regular FBS medium), spheres (prepared in regular FBS medium), and neuroendocrine
cells (in CSF medium). Columns and vertical bars are means ± SD of 4 separate experiments. * indicates statistically significant difference in
colony numbers between LNCaP and neuroendocrine cells, P<0.05. C. Matrigel migration assay. This figure shows the number of invasive
cells per membrane of LNCaP cells (maintained in regular FBS medium), spheres (regular FBS medium), and neuroendocrine cells (CSF
medium) from the Matrigel chamber invasion assay. Chemoattractant used in the lower chamber: solid bar (■) indicates regular FBS; open
bar (▫) indicates charcoal-stripped FBS (CSF). Columns and vertical bars indicate the means ± SD of four separate experiments.
www.impactjournals.com/oncotarget
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spheres (approximately 5.7 folds), as compared to that of
the parental LNCaP cells (Figure 5A). Figure 5A shows
additionally that the level of acetylation of histone H3
lysine position 4 (H3K4) was increased (approximately
5 folds) in the spheres. Both the histone acetylation and
DNMT1 changes were reported to be responsible for
reactivating GSTP1 [15]. Activation of GSTP1 was further
confirmed by in situ immunohistochemical staining of the
sphere cells in paraffin blocks (Figure 5B). The sphere
cells showed more intense staining. More sphere cells
were positive for GSTP1 expression than LNCaP cells.
The results indicated that the spheres had epigenomic
signatures distinct from the parental LNCaP cells.

The sphere cells can self-renew in media with and without
androgen, and both can be maintained as cell lines in longterm cultures. The phenotype of the LNCaP sphere cells is
distinct from that of the parental LNCaP cells. The distinct
characteristics of the sphere cells include the expression
of CD44, higher expression levels of AR, Sp1, and PSA,
as well as distinct epigenetic markers (Table 2). When
androgen was depleted, the adherent spheres underwent
differentiation to neuroendocrine cells. Like other types
of tumor spheres, the LNCaP prostate cancer spheres have
properties of cancer stem cells capable of self-renewal and
differentiation [24–28]. Furthermore, the sphere formation
property after PEITC treatment appears to be intrinsic to
LNCaP cells, since sphere formation was reproducible in
GFP-LNCaP cells, but no spheres from DU-145 cells and
rare small spheres from PC-3 cells were observed under
similar treatment. This may suggest that there may be
unique epigenetic abnormalities in LNCaP cells.

DISCUSSION
This study established prostate cancer cell spheres
through treatment with an epigenetic modulator PEITC.

Figure 5: Epigenetic marks of LNCaP sphere cells. A. Immunoblotting showing the expression levels of DNMT1 (DNA
methytransferase 1), GSTP1 (π-class glutathione S-transferase), and acetylated histone H3 lysine 4 (H3K4) in LNCaP cells and sphere
cells maintained in regular FBS medium. β-actin was used as a loading control. B. Immunohistochemical staining of GSTP1 on paraffin
embedded preparations of LNCaP cells (left), and sphere cells (right) maintained in regular FBS medium.
www.impactjournals.com/oncotarget
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Table 2: Comparison of the characteristics of LNCaP cells, spheres, and neuroendocrine cells
Markers and Properties

Characteristics
LNCaP

Spheres

Neuroendocrine cells

Pancytokeratin

+/−

−

+++

Neuro-specific enolase

+/−

−

+++

Serotonin

−

−

+

AR

++

+++

+

Sp1

+/−

+++

−

PSA

+

+++

−

Ki67

++

+++

+

CD44

<2%

46%

67%

Colony formation

+++

++

+

Invasive cells

++

+

+++

DNMT1

+++

++

+

GSTP1

+

++++

+++

Definitions: +/−: focally and weakly positive; −: negative; +: weakly positive; ++: moderately positive; >=+++: strongly
positive.
Abbreviations: AR: androgen receptor; DNMT: DNA methyltransferase; GSTP: glutathione-S-transferase;
The current finding of the prostate cancer
sphere cells is in line with earlier reports of androgenindependent prostate cancer stem cells [5, 6]. However,
this is the first report of the dual capability of PCSC
to self-renew with and without androgen. The results
demonstrated that when the androgen quantity is
decreased; the PCSC may reprogram to self-renew
without androgen, and differentiate into progeny. The
progeny could also reprogram and de-differentiate to
PCSC when androgen is increased. Thus tumor cells may
differentiate back and forth, capable of adapting to the
microenvironment, growing according to the quantity of
androgen.
The shuttle between PCSC and progeny differen
tiation may shed light on the drug resistance to androgen
deprivation therapy. When the androgen-sensitive tumor
cells are eliminated by androgen deprivation therapy,
PCSC may be spared since they can survive in androgen
insufficient conditions. Under low androgen concentration,
PCSCs differentiate to progenies with low AR expression
and survive in an androgen-depleted condition, thus
becoming refractory to androgen deprivation therapy. The
neuroendocrine cells, after differentiating from spheres in
androgen deficient condition, were demonstrated to revert
back to spheres upon addition of DHT, in a concentrationdependent manner. This indicates that the reversible
process is androgen-dependent. However, the mechanism
of de-differentiation from neuroendocrine cells to
spheres remains unclear, as stem and progenitor cell
differentiation is classically uni-directional. It has been
www.impactjournals.com/oncotarget

shown that epithelial-to-mesenchymal transition (EMT)
and vice versa can take place [29]. Whether the shuttling
between spheres and neuroendocrine cells represents
a new type of EMT (i.e., epithelial to neuroendocrine
transition) remains to be determined. We hypothesize that
androgenomic alterations govern the shuttling between
sphere PCSC and neuroendocrine cells (Figure 6). In
the absence of androgen, such as complete androgen
blockade therapy or castration, androgenomic shutdown
in the PCSC may lead to deceleration in proliferation
and self-renewal, and initiate the differentiation process
to progeny such as neuroendocrine cells (NEC). In the
presence of androgen, the androgenome in the NEC may
reprogram, allowing de-differentiation to spheres and
the regaining of their properties. Albeit rare, prostate
cancer with neuroendocrine cell features is known to
have an aggressive nature with a poor prognosis [9].
The NEC in this study had demonstrated tumorigenic
and invasive activities, as well as cellular and molecular
features resembling NEC in clinical tumors. The current
culture system may serve as a model for investigating this
population of cancer cells.
In comparison to the LNCaP cells, the sphere cells
displayed distinct epigenetic marks at the two major
epigenetic transcriptional controls, i.e., covalent modi
fication of histones and DNA methylation. They include
enhancement of acetylation at histone H3K4, and activation
of hypermethylated GSTP1 gene. Exposure to PEITC was
previously demonstrated to reactivate the GSTP1 gene and
its detoxification function, by inhibiting histone deacetylases
26574
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Figure 6: Hypothesis of a prostate cancer sphere model system. Androgen-dependent prostate cancer cells form spheres, with
characteristics of prostate cancer stem cells (PCSC), due to epigenomic alterations mediated by an epigenetic modulator PEITC. This
step is irreversible. PCSC retain tumorigenic potential and have dual proliferation capabilities allowing self-renewal in the presence and
absence of androgen. In the absence of androgen (such as complete androgen blockade therapy/castration), PCSC cells are attenuated in
proliferation and initiated differentiation process to neuroendocrine cells (NEC). The androgenome in the NEC cells are reprogramed in
the presence of androgen, thereby the NEC cells can de-differentiate to spheres. Since LNCaP cells are epithelial in origin, this step may
represent a new phenomenon, epithelial-to-neuroendorine and neuroendocrine-to-epithelial transition.

and promoter hypermethylation of the GSTP1 gene [15, 16].
PEITC might also regulate the molecules involved in cellular
adherence, which resulted in detachment of PEITC-treated
cells from flasks, leading to sphere formation in culture
supernatant. The detailed mechanism of PEITC effect on
these cells remains to be further investigated. They include
whether PEITC causes specific changes in cellular organelle
structure [30], and gene expression for PCSC development
[31], and whether PEITC affects telomere stability, as AR is
associated with telomeres [32]. An investigation of signaling
pathways mediated by PEITC relating to sphere development
is currently being pursued.
This study described a simple, unique and
reproducible methodology for establishment and
maintenance of prostate cancer spheres. The sphere
cells have properties of PCSCs since they can selfrenew and differentiate into neuroendocrine cells.
Furthermore, the sphere cells can be manipulated to
shuttle between spheres and neuroendocrine cells by
adjusting androgen concentration. This has additionally
described a method for establishment of a cell line
that can shuttle between two distinct types of cells
derived from the LNCaP cell line. This methodology
might be applicable for establishment of spheres from
www.impactjournals.com/oncotarget

other cell lines. More and more biomarkers are being
discovered and validated for clinical diagnosis and
therapeutic development [33–36]. Targeted therapy
with small molecule inhibitors are translated rapidly to
clinical applications [37–43]. The PCSC sphere cell line
established herein can thus be used to screen for novel
agents for prostate cancer therapy.

MATERIALS AND METHODS
Cell lines and reagents
Human prostate cancer LNCaP cell line at
passage 21 and 31 were purchased from ATCC
and characterized for fewer than 6 months before
experimentation. An LNCaP cell line labeled with green
fluorescent protein (GFP-LNCaP) was purchased from
AntiCancer, Inc. (San Diego, California). LNCaP cells
were maintained in RPMI-1640 medium supplemented
with either 10% fetal bovine serum (regular FBS), or
with 10% steroid hormone-depleted charcoal dextranstripped FBS (Hyclone) (CSF), and antibiotics.
5-αdihydrotestosterone (DHT) was purchased from
Sigma Chemical Company.
26575
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Immunohistochemistry

described previously [45, 46]. The cells were fixed with
80% ethanol at 4 oC, and incubated on ice before the
DNA was stained with propidium iodide (50 μg/ml).The
expression levels of cellular proteins were determined by
quantitative Western blotting as previously described [47,
48]. Images were recorded using chemilmager 5500 (Alpha
Innotech). Antibodies were used to detect the following:
C-terminal region of the androgen receptor (AR) (Santa
Cruz Biotechnology;I299), Sp1 (Santa Cruz Biotechnology;
E1304), prostate specific antigen (PSA) (Santa Cruz
Biotechnology; C0414), DNA methytransferase 1 (DNMT1)
(Santa Cruz Biotechnology; C0306), π-class glutathione
S-transferase (GSTP1) (Santa Cruz Biotechnology; A1513),
and β-actin (Sigma; 082M4781). The relative abundance of
each protein obtained from the blot was calculated relative
to the quantity of β-actin. Cells with surface CD44 were
detected by a flow cytometric method with 10,000 live cell
events analyzed per sample [49]. Cells were immunostained
with a fluorescent conjugated monoclonal antibody against
CD44 (BD Biosciences; clone 24345), and fixed with 1%
paraformaldehyde. The proportion of the positively stained
cells was determined against a background of cells stained
with an isotype control.

Cultured cells were fixed in 10% neutral buffered
formalin, and the centrifuged cells underwent routine
paraffin-embedding as a cell block by the plasma thrombin
method. Three to four micrometer sections of the paraffinembedded cell blocks were prepared for histology study
and for immunohistochemistry. Monoclonal antibodies for
the following proteins were used: pan cytokeratin (Ventana;
AE1/AE3/PCK26); serotonin (Dako; 5HT-H209, 1:5
dilutions); neuro-specific enolase (Ventana; MRQ-55); Ki67
(Ventana; 30-9); androgen receptor (Ventana; SP107); π-class
glutathione S-transferase (Santa Cruz biotechnology; A1513).
Automated immunohistochemical system Ventana Bench
Mark Ultra was used. Ventana ultra detection kit was used for
staining and visualization. Positive controls included known
pan cytokeratin, neuro-specific enolase, serotonin, Ki67, AR,
and π-class glutathione S-transferase. Negative controls had
primary antibody replaced by buffer and processed with the
specimen slides. Immunohistochemistry was performed at the
Department of Pathology, Westchester Medical Center, and
immuostaining evaluated by an intensity scoring procedure.
Cells were graded for the staining intensity as negative (-),
focal and weak (±), weak to moderate (+), or strong (+++).
Evaluations of specimen staining were performed by an
independent pathologist without knowing the nature of the
experiments.

Clonogenesis and cell invasion assay
Clonogenesis of cancer cells was assayed by a
soft-gel semi-solid culture as previously described [49].
Essentially, 400-800 single cells were seeded in 1.5 ml
soft-agar gel with RPMI-1640 medium with either 10%
regular FBS or charcoal-stripped FBS per 35 x 10-mm
culture dish. At least five duplicate dishes were used for
each condition. Individual colonies with at least 30 cells
were enumerated. Cell invasion assay was performed
using a BD BioCoat Matrigel Invasion chamber (BD
Biosciences) according to the procedure described. The
upper chambers were seeded with 5 x 104 of LNCaP cells,
dissociated cells from the spheres, or neuroendocrine cells
which were scraped from the cultures. Chemoattractants
were loaded in the lower chamber. These included
10% FBS, or 10% charcoal–stripped FBS as indicated.
Triplicate samples were assayed. Cells migrated into the
lower chamber were fixed, stained with 1% toluidine blue
and counted under light microscope.

LNCaP cell sphere development
LNCaP cells seeded at 1.5 x 105/ml of RPMI-1640
medium with 10% regular FBS medium were exposed
to 4 μM phenethyl isothiocyanate (PEITC). PEITC was
supplemented every 2-3 days. PEITC was purchased from
LKT Labs with 98% purity, which was prepared in phosphate
buffered saline and DMSO [15, 16]. Cultures supplemented
with vehicle control were used in every experiment. The nonadherent cells in the supernatants, after exposure to PEITC
for 4-10 days, were collected in regular culture flasks, which
were continuously exposed to 3 μM PEITC for 8-12 days.
The non-adherent spheres were collected by centrifugation,
and cultured in flasks with ultralow attachment surface
(Fisher Scientific). They were maintained in RPMI-1640
medium with 10% FBS without PEITC for further studies.
Adherent sphere culture was obtained by culturing the
floating spheres in regular culture flasks. Individual spheres
were isolated with limiting dilution in 96 well plates [44].
Dissociation of cells from spheres was aided with a nonenzymatic cell dissociation solution (Sigma).The cells were
further dispersed by repetitive pipetting through a glass
Pasteur pipette, in combination with trypsin digestion and
gently passing through 17 G, and 25 G needles.

Statistical analysis
All data were presented as mean ± SD from multiple
independent experiments. The mean values of two groups
of data were compared by the two-tailed Student’s t-test,
with P<0.05 considered to be statistically significant.

Cell cycle analyses and immunoblotting
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